DE69330842T2 - Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration - Google Patents

Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration

Info

Publication number
DE69330842T2
DE69330842T2 DE69330842T DE69330842T DE69330842T2 DE 69330842 T2 DE69330842 T2 DE 69330842T2 DE 69330842 T DE69330842 T DE 69330842T DE 69330842 T DE69330842 T DE 69330842T DE 69330842 T2 DE69330842 T2 DE 69330842T2
Authority
DE
Germany
Prior art keywords
gml
dopa
parkinson
therapy
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330842T
Other languages
English (en)
Other versions
DE69330842D1 (de
Inventor
Gino Toffano
Aurelio Romeo
Stephen Drake Skaper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Medidom SA
Original Assignee
Fidia Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA
Publication of DE69330842D1 publication Critical patent/DE69330842D1/de
Application granted granted Critical
Publication of DE69330842T2 publication Critical patent/DE69330842T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69330842T 1992-03-13 1993-03-12 Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration Expired - Lifetime DE69330842T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Publications (2)

Publication Number Publication Date
DE69330842D1 DE69330842D1 (de) 2001-10-31
DE69330842T2 true DE69330842T2 (de) 2002-04-04

Family

ID=11362423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330842T Expired - Lifetime DE69330842T2 (de) 1992-03-13 1993-03-12 Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration

Country Status (8)

Country Link
US (1) US6620792B1 (de)
EP (2) EP0630250A1 (de)
JP (1) JP2872809B2 (de)
AT (1) ATE206053T1 (de)
DE (1) DE69330842T2 (de)
ES (1) ES2161953T3 (de)
IT (1) IT1254280B (de)
WO (1) WO1993017691A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259176B (it) * 1992-10-23 1996-03-11 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
US7842677B2 (en) * 2001-08-29 2010-11-30 Seneb Biosciences, Inc. Synthetic ganglioside derivatives and compositions thereof
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
US7943750B2 (en) * 2007-06-18 2011-05-17 Laboratoire Medidom S.A. Process for obtaining pure monosialoganglioside GM1 for medical use
CN101732331B (zh) * 2008-11-20 2012-05-23 北京四环制药有限公司 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104490837A (zh) * 2014-12-30 2015-04-08 哈尔滨医科大学科技开发总公司 单唾液酸四己糖神经节苷脂钠的口服制剂
RU2632710C2 (ru) * 2016-03-31 2017-10-09 Лонг Шенг Фарма Лимитед Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе
CN108815131B (zh) * 2018-09-11 2021-01-01 四川奇格曼药业有限公司 一种神经节苷脂缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
IT1208751B (it) * 1986-06-30 1989-07-10 Fidia Farmaceutici Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
IT1235161B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisogangliosidi
IT1249034B (it) * 1990-06-29 1995-02-11 Fidia Spa Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
IT1253832B (it) * 1991-08-01 1995-08-29 Fidia Spa Derivati di gangliosidi

Also Published As

Publication number Publication date
WO1993017691A2 (en) 1993-09-16
JPH07508258A (ja) 1995-09-14
IT1254280B (it) 1995-09-14
ATE206053T1 (de) 2001-10-15
EP0770389A1 (de) 1997-05-02
JP2872809B2 (ja) 1999-03-24
ITMI920591A1 (it) 1993-09-13
EP0630250A1 (de) 1994-12-28
DE69330842D1 (de) 2001-10-31
WO1993017691A3 (en) 1993-11-11
ES2161953T3 (es) 2001-12-16
ITMI920591A0 (it) 1992-03-13
EP0770389B1 (de) 2001-09-26
US6620792B1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
DE59107331D1 (de) Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DE69129082D1 (de) Vom Stoffwechselbedarf gesteuerter taktanpassender Schrittmacher
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DK0768312T3 (da) Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron
OA08581A (en) Treatment of diseases caused by retroviruses.
BR8804188A (pt) Processo para controlar a aspereza da superficie de um filme
DK90089D0 (da) Hudbehandlingspraeparat
DE69330842D1 (de) Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration
IT1221826B (it) Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
BR8501792A (pt) Autoclave para o tratamento de licor de cacau
IT1212143B (it) Composizione ad attivita'tricogena.
IT8247513A0 (it) Procedimento per il trattamento di substrati tessili costituenti da poliammidi naturali o sintetiche
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DK0388275T3 (da) Dermatologiske og kosmetoligiske præparater, der er baseret på alkylcarboxamid og zinksalte og er nyttige til behandling af serborrhoisk dermatitis og/eller serborrhoiske lidelser
ATE162717T1 (de) Behandlung kardialer dysfunktion mit 15- ketoprostaglandinderivaten
DK671187D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
IT8519042A0 (it) Impiego di chinoloni nel trattamento di malattie cardiache.!
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses
MX9203508A (es) 1,7-difenil-3-metilaza -7-ciano-8-metilnonano para usarse en el tratamiento de enfermedades.
ATE63685T1 (de) Hautbehandlungsmittel.
IT8722869V0 (it) Dispositivo perfezionato per l'abbronzatura artificiale integrale o parziale.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRE MEDIDOM S.A., GENF/GENEVE, CH